Hongping Zheng1, Yotsawat Pomyen1,2, Maria Olga Hernandez1, Caiyi Li3, Ferenc Livak3, Wei Tang1, Hien Dang1, Tim F Greten4, Jeremy L Davis4, Yongmei Zhao5, Monika Mehta5, Yelena Levin5, Jyoti Shetty5, Bao Tran5, Anuradha Budhu1, Xin Wei Wang1. 1. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Translational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand. 3. Flow Cytometry Core Facility, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 5. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD.
Abstract
Intratumor molecular heterogeneity of hepatocellular carcinoma is partly attributed to the presence of hepatic cancer stem cells (CSCs). Different CSC populations defined by various cell surface markers may contain different oncogenic drivers, posing a challenge in defining molecularly targeted therapeutics. We combined transcriptomic and functional analyses of hepatocellular carcinoma cells at the single-cell level to assess the degree of CSC heterogeneity. We provide evidence that hepatic CSCs at the single-cell level are phenotypically, functionally, and transcriptomically heterogeneous. We found that different CSC subpopulations contain distinct molecular signatures. Interestingly, distinct genes within different CSC subpopulations are independently associated with hepatocellular carcinoma prognosis, suggesting that a diverse hepatic CSC transcriptome affects intratumor heterogeneity and tumor progression. CONCLUSION: Our work provides unique perspectives into the biodiversity of CSC subpopulations, whose molecular heterogeneity further highlights their role in tumor heterogeneity, prognosis, and hepatic CSC therapy. (Hepatology 2018;68:127-140). Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Intratumor molecular heterogeneity of hepatocellular carcinoma is partly attributed to the presence of hepatic cancer stem cells (CSCs). Different CSC populations defined by various cell surface markers may contain different oncogenic drivers, posing a challenge in defining molecularly targeted therapeutics. We combined transcriptomic and functional analyses of hepatocellular carcinoma cells at the single-cell level to assess the degree of CSC heterogeneity. We provide evidence that hepatic CSCs at the single-cell level are phenotypically, functionally, and transcriptomically heterogeneous. We found that different CSC subpopulations contain distinct molecular signatures. Interestingly, distinct genes within different CSC subpopulations are independently associated with hepatocellular carcinoma prognosis, suggesting that a diverse hepatic CSC transcriptome affects intratumor heterogeneity and tumor progression. CONCLUSION: Our work provides unique perspectives into the biodiversity of CSC subpopulations, whose molecular heterogeneity further highlights their role in tumor heterogeneity, prognosis, and hepatic CSC therapy. (Hepatology 2018;68:127-140). Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Jittiporn Chaisaingmongkol; Anuradha Budhu; Hien Dang; Siritida Rabibhadana; Benjarath Pupacdi; So Mee Kwon; Marshonna Forgues; Yotsawat Pomyen; Vajarabhongsa Bhudhisawasdi; Nirush Lertprasertsuke; Anon Chotirosniramit; Chawalit Pairojkul; Chirayu U Auewarakul; Thaniya Sricharunrat; Kannika Phornphutkul; Suleeporn Sangrajrang; Maggie Cam; Ping He; Stephen M Hewitt; Kris Ylaya; Xiaolin Wu; Jesper B Andersen; Snorri S Thorgeirsson; Joshua J Waterfall; Yuelin J Zhu; Jennifer Walling; Holly S Stevenson; Daniel Edelman; Paul S Meltzer; Christopher A Loffredo; Natsuko Hama; Tatsuhiro Shibata; Robert H Wiltrout; Curtis C Harris; Chulabhorn Mahidol; Mathuros Ruchirawat; Xin W Wang Journal: Cancer Cell Date: 2017-06-22 Impact factor: 31.743
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Ying Fu; Daniel J Urban; Roger R Nani; Yi-Fan Zhang; Nan Li; Haiying Fu; Hamzah Shah; Alexander P Gorka; Rajarshi Guha; Lu Chen; Matthew D Hall; Martin J Schnermann; Mitchell Ho Journal: Hepatology Date: 2019-02-19 Impact factor: 17.425
Authors: Lichun Ma; Maria O Hernandez; Yongmei Zhao; Monika Mehta; Bao Tran; Michael Kelly; Zachary Rae; Jonathan M Hernandez; Jeremy L Davis; Sean P Martin; David E Kleiner; Stephen M Hewitt; Kris Ylaya; Bradford J Wood; Tim F Greten; Xin Wei Wang Journal: Cancer Cell Date: 2019-10-03 Impact factor: 31.743
Authors: Bin Chen; Lana Garmire; Diego F Calvisi; Mei-Sze Chua; Robin K Kelley; Xin Chen Journal: Nat Rev Gastroenterol Hepatol Date: 2020-01-03 Impact factor: 46.802